CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Key Points CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity. CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.